Oruka Therapeutics, Inc. Income Tax Examination, Penalties and Interest Expense
Oruka Therapeutics, Inc. (ORKA) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-01.
Discontinued › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2024-02-01
- Oruka Therapeutics, Inc. income tax examination, penalties and interest expense for fiscal 2023 was $0.00.
- Oruka Therapeutics, Inc. income tax examination, penalties and interest expense for fiscal 2022 was $0.00.
- Oruka Therapeutics, Inc. income tax examination, penalties and interest expense for fiscal 2021 was $0.00.
- Oruka Therapeutics, Inc. income tax examination, penalties and interest expense for fiscal 2020 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-01 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-01 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-24 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-14 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-18 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-18 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-27 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-22 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-21 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-17 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-19 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-20 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |